Danaher Corporation DHR is backed by multiple tailwinds despite some margin pressure due to raw material cost inflation and supply chain disruptions. DHR is benefiting from strong performance of the Life Sciences segment due to healthy demand for bioprocessing products. DHR anticipates base business core revenue growth of high-single digits for the third quarter.